The Investigators plan to study the innate and adaptive immune response, the inflammatory response, and associated complications such as complement activation and neurological damage in SARS-Cov-2 infected individuals. Patients with mild, moderate and severe COVID-19 disease will be enrolled.
The severity of coronavirus disease 2019 (COVID-19) ranges from asymptomatic infection to severe illness requiring mechanical ventilation. Immunological factors which lead to severe disease in certain COVID-19 patients remain incompletely understood. Neurological damage and complement activation may be a consequence of excess inflammation in severe COVID-19. The investigators plan to study the innate and adaptive immune response and potentially associated complications such as neurological damage and complement activation in mild, moderate and severe COVID-19 courses.
Study Type
OBSERVATIONAL
Enrollment
88
Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.
Bern University Hospital
Bern, Switzerland
Cytokine response to SARS-Cov-2
Measurement of cytokine concentration (pg/ml) in serum (IL-6, IL-8, IL-1b,TNF-alpha)
Time frame: At enrollment
Cytokine response to SARS-Cov-2
Measurement of cytokine concentration (pg/ml) in serum (IL-6, IL-8, IL-1b,TNF-alpha)
Time frame: 28 days (+/-7) after enrollment
Innate immune response to SARS-Cov-2
Measurement of HLA-DR expression on CD14+ cells (flowcytometry)
Time frame: At enrollment
Innate immune response to SARS-Cov-2
Measurement of HLA-DR expression on CD14+ cells (flowcytometry)
Time frame: 3 days after enrollment
Innate immune response to SARS-Cov-2
Measurement of HLA-DR expression on CD14+ cells (flowcytometry)
Time frame: 5 days after enrollment
Humoral immune response
Measurement of neutralizing SARS-Cov-2 antibody concentrations (plaque reduction assay)
Time frame: At enrollment
Cell mediated immune response
Measurement of frequencies of SARS-Cov-2 specific T-cells (ELISPOT assay)
Time frame: At enrollment
Cell mediated immune response
Measurement of frequencies of SARS-Cov-2 specific T-cells (ELISPOT assay)
Time frame: 28 days (+/-7) after enrollment
Neurological damage
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Measurement of neurofilament light chains in serum (on ELLA platform; Protein Simple, Bio-techne)
Time frame: At enrollment
Neurological damage
Measurement of neurofilament light chains in serum (on ELLA platform; Protein Simple, Bio-techne)
Time frame: 28 days (+/-7) after enrollment
Complement activation
Measurement of factor B, factor H, factor I, C3a, C4a, C5a, SC5b9
Time frame: At enrollment
Complement activation
Measurement of factor B, factor H, factor I, C3a, C4a, C5a, SC5b9
Time frame: 28 days (+/-7) after enrollment